ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results

Author's Avatar
Oct 20, 2022

ImmunoGen+Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 4, 2022 to discuss its third quarter 2022 operating results. Management will also provide a brief update on the business.